Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG Distribution in Breast Cancer After Neoadjuvant Therapy
NCT02032563Phase 2Unknown
- Sponsor
- Institut Jules Bordet
- Start
- Dec 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of indocyanine green in breast cancer, sponsored by Institut Jules Bordet. Primary endpoint: Fluorescence intensity of tumoral lesions, scars and healthy tissues at 1 week. Status: unknown.
02
Drugs
indocyanine green
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02032563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02032563.